Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
The company will submit its comprehensive response on these observations to the US FDA
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
The company has extended its full co-operation and support to the officials of the Income Tax Department
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The product is expected to be launched in June 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Subscribe To Our Newsletter & Stay Updated
